Improvement of Lumbar Bone Mass after Infliximab Therapy in Crohn’s Disease Patients
BACKGROUND: Patients with Crohn’s disease (CD) have a high risk of developing osteoporosis, but the mechanisms underlying bone mass loss are unclear. Elevated proinflammatory cytokines, such as tumour necrosis factor-alpha (TNFα), have been implicated in the pathogenesis of bone resorption.
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2007-01-01
|
| Series: | Canadian Journal of Gastroenterology |
| Online Access: | http://dx.doi.org/10.1155/2007/216162 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832561610185506816 |
|---|---|
| author | Marina Mauro Vladimir Radovic David Armstrong |
| author_facet | Marina Mauro Vladimir Radovic David Armstrong |
| author_sort | Marina Mauro |
| collection | DOAJ |
| description | BACKGROUND: Patients with Crohn’s disease (CD) have a high risk of developing osteoporosis, but the mechanisms underlying bone mass loss are unclear. Elevated proinflammatory cytokines, such as tumour necrosis factor-alpha (TNFα), have been implicated in the pathogenesis of bone resorption. |
| format | Article |
| id | doaj-art-044bfa48e1834078aa381ad20bca51d1 |
| institution | Kabale University |
| issn | 0835-7900 |
| language | English |
| publishDate | 2007-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology |
| spelling | doaj-art-044bfa48e1834078aa381ad20bca51d12025-02-03T01:24:32ZengWileyCanadian Journal of Gastroenterology0835-79002007-01-01211063764210.1155/2007/216162Improvement of Lumbar Bone Mass after Infliximab Therapy in Crohn’s Disease PatientsMarina Mauro0Vladimir Radovic1David Armstrong2Intestinal Disease Research Program & Division of Gastroenterology, McMaster University, Hamilton, Ontario, CanadaIntestinal Disease Research Program & Division of Gastroenterology, McMaster University, Hamilton, Ontario, CanadaIntestinal Disease Research Program & Division of Gastroenterology, McMaster University, Hamilton, Ontario, CanadaBACKGROUND: Patients with Crohn’s disease (CD) have a high risk of developing osteoporosis, but the mechanisms underlying bone mass loss are unclear. Elevated proinflammatory cytokines, such as tumour necrosis factor-alpha (TNFα), have been implicated in the pathogenesis of bone resorption.http://dx.doi.org/10.1155/2007/216162 |
| spellingShingle | Marina Mauro Vladimir Radovic David Armstrong Improvement of Lumbar Bone Mass after Infliximab Therapy in Crohn’s Disease Patients Canadian Journal of Gastroenterology |
| title | Improvement of Lumbar Bone Mass after Infliximab Therapy in Crohn’s Disease Patients |
| title_full | Improvement of Lumbar Bone Mass after Infliximab Therapy in Crohn’s Disease Patients |
| title_fullStr | Improvement of Lumbar Bone Mass after Infliximab Therapy in Crohn’s Disease Patients |
| title_full_unstemmed | Improvement of Lumbar Bone Mass after Infliximab Therapy in Crohn’s Disease Patients |
| title_short | Improvement of Lumbar Bone Mass after Infliximab Therapy in Crohn’s Disease Patients |
| title_sort | improvement of lumbar bone mass after infliximab therapy in crohn s disease patients |
| url | http://dx.doi.org/10.1155/2007/216162 |
| work_keys_str_mv | AT marinamauro improvementoflumbarbonemassafterinfliximabtherapyincrohnsdiseasepatients AT vladimirradovic improvementoflumbarbonemassafterinfliximabtherapyincrohnsdiseasepatients AT davidarmstrong improvementoflumbarbonemassafterinfliximabtherapyincrohnsdiseasepatients |